Authors
Yasushi Isobe, Tsuyoshi Muta, Yosuke Masamoto, Go Yamamoto, Shingo Kurahashi, Yoshihiro Kameoka, Shuichi Ota, Eri Matsuki, Kazutaka Ozeki, Takanori Toyama, Naoki Takahashi, Takahiro Kumode, Nobuyuki Aotsuka, Takuro Yoshimura, Hideto Tamura, Ai Omi, Kazuhiro Shibayama, Yuma Fujimori, Kensuke Kojima, Jun Takizawa, Hirokazu Nagai, Junji Suzumiya, Sadao Aoki
Published in
Leukemia & lymphoma. Pages 1-10. Nov 17, 2026. Epub Nov 17, 2026.
Abstract
The Orbit study confirmed safety and effectiveness of ibrutinib in Japanese patients with treatment-naïve and relapsed/refractory chronic lymphocytic leukemia (CLL). This post-hoc analysis evaluated ibrutinib treatment patterns and impact of dose modifications, stratifying patients into three subgroups: (1) continuous full-dose (420 mg/day); (2) initially full-dose then discontinued and restarted; (3) reduced starting dose. Dose modifications after resumption in subgroup 2 were mainly due to adverse events (78.5%), and reduced starting doses in subgroup 3 were mainly due to adverse event concerns (79.7%). In subgroup 3, 89.2% experienced dose modification and 32.3% increased to 420 mg/day. Mean relative dose intensity was higher in subgroup 1 than 2/3 (92.5% vs 73.8%/48.1%). The 36-month progression-free survival (PFS)/overall survival rates were 67.9%/88.3%, 75.9%/89.2%, and 86.0%/86.5%, respectively. Subgroups 1 and 3 mainly included biologically unfavorable diseases and elderly vulnerable patients, respectively. Individualized ibrutinib dosing may be effective in maintaining CLL treatment even in real-world practice.
PMID:
43043006
Bibliographic data and abstract were imported from PubMed on 17 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 1
- Comments 0